Who are AzaSite®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Intravenous Clarithromycin, Altabax (R), Tedizolid IV, Azithromycin 3 days, Azithromycin and amoxicillin, P.O roxithromycin 150 mg*2/d for 7 days.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/azasite.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

AzaSite® — Competitive Intelligence Brief

AzaSite® (AzaSite®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Macrolide antibiotic. Area: Ophthalmology.

marketed Macrolide antibiotic Bacterial 50S ribosomal subunit Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

AzaSite® (AzaSite®) — Merck Sharp & Dohme LLC. AzaSite is an azithromycin ophthalmic suspension that reduces bacterial load and inflammatory mediators in the eye to treat bacterial conjunctivitis and meibomian gland dysfunction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AzaSite® TARGET	AzaSite®	Merck Sharp & Dohme LLC	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Intravenous Clarithromycin	Intravenous Clarithromycin	University of Athens	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Altabax (R)	Altabax (R)	St. Luke's-Roosevelt Hospital Center	marketed	Pleuromutilin antibiotic	Bacterial 50S ribosomal subunit
Tedizolid IV	Tedizolid IV	University of Southern California	marketed	Oxazolidinone antibiotic	Bacterial 50S ribosomal subunit
Azithromycin 3 days	Azithromycin 3 days	University of Oxford	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit
Azithromycin and amoxicillin	Azithromycin and amoxicillin	University of Alabama at Birmingham	marketed	Macrolide and beta-lactam antibiotic combination	Bacterial 50S ribosomal subunit (azithromycin); bacterial cell wall peptidoglycan (amoxicillin)
*P.O roxithromycin 150 mg2/d for 7 days**	P.O roxithromycin 150 mg*2/d for 7 days	Western Galilee Hospital-Nahariya	marketed	Macrolide antibiotic	Bacterial 50S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Macrolide antibiotic class)

Pfizer · 6 drugs in this class
Grünenthal GmbH · 4 drugs in this class
Merck Sharp & Dohme LLC · 3 drugs in this class
University of Taubate · 2 drugs in this class
Lihir Medical Centre · 2 drugs in this class
Thomas Jefferson University · 2 drugs in this class
Copenhagen Studies on Asthma in Childhood · 1 drug in this class
Ain Shams Maternity Hospital · 1 drug in this class
Celltrion · 1 drug in this class
London School of Hygiene and Tropical Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AzaSite® — Competitive Intelligence Brief. https://druglandscape.com/ci/azasite. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab